
Pfizer is expected to announce a record £26bn in sales revenue from its Covid-19 vaccine during 2021 – enough to fill the funding shortfall in the world’s dose-sharing programme seven times over.
The bumper income, which is expected to be revealed at its annual earnings call on Tuesday, come as the Covax initiative is almost out of money.